Managers

Social Scene: GPs, LPs optimistic about the future and other impressions from Venture Alpha East

Editor's Letter: Sequoia stands strong; 500 Startups is key VC firm to watch

IPO Profile: Aeglea Bio was the only VC-backed company to launch an IPO in April

The Austin, Texas-based drug developer raised $54.7 million from investors prior to its April 7 IPO on th Nasdaq

Consumer tech-focused Binary Capital seeks second fund

San Francisco-based Binary Capital, which raised $125 million for its debut fund in 2014, is seeking a second fund. No target is listed on the firm's regulatory document.

Boston's .406 Ventures seeks $80 mln for its first opportunity fund

Boston-based .406 Ventures, which last year closed its third early-stage fund with $217 million in commitments, has filed to raise $80 million for an opportunity fund, according to a regulatory document.

On the Bleeding Edge: Impressions from IVP spring party and other VC-related musings

What I learned about The House Fund from the IVP party, and my thoughts on the the VC-backed Stemcentrx getting acquired

Column Group raises third fund at $535 mln

Revisiting my vision for the NVCA

Nearly three years in, NVCA President Bobby Franklin says the group is realizing its vision and becoming the voice of the entrepreneurial ecosystem

AbbVie to buy venture-backed Stemcentrx in deal that could reach $10 bln

AbbVie Inc agreed to acquire venture-backed Stemcentrx in a deal valued at about $5.8 billion, which includes $2 billion in cash and the remainder in stock. Backers include Fidelity Investments. The company, which was backed by Artis Ventures and Founders Fund.

Sunstone closes first fund at $300 mln

Sunstone Partners closed a $300 million first fund, Sunstone Partners I, according to a press release. The fund had an initial target of $200 million and was oversubscribed.